Oncology KnowledgeBASE



New Medicine

Product Designation:

Breastin

Descirption :

Breastin is a cold patented extract obtained from Nerium oleander with potential anticancer activity against some tumors.

Primary Developer:

Applied Company For Therapeutic Preparations L.C.C. in collaboration with Oncotest LLC. Freiburg-Germany.

Product Specifications:

Therapeutic Indications: Breast, lung, prostate, pancreas and colorectal

adenocarcinomas

Therapeutic Category…….Targeted drug therapy

Drug Category ………… A fraction from N. Oleander that contains mainly two

glycosides plus few other compounds.

Mechanism………………Antioncogenic, cell- cycle inhibition, cytotoxic effects

are induced by the inhibition of the plasma bound Na+/

K+- ATPase.

Mechanism Details…… Breastin inhibits cell division at the S- phase. In addition, it

has antioncogenic activity against some oncogens., the

cytotoxic effects are induced by the inhibition of the plasma

membrane bound Na+/ K+ ATPase as known for cardiotonic

effects. These mechanism of actions are supported by clinical

evidence, which demonstrate that Breastin is specific in its

activity against some cancers such as breast, lung, pancreas,

prostate lung adenocarcinomas.

Preclinical History:

Large cell lung, prostate, colon, uterus, pleuramesothelioma cell

lines are particularly sensitive to cytotoxic effects of Breastin.

Breastin is also potent against melanoma, bladder, renal and

ovarian cell lines. Breastin cause profound inhibition of tumor

growth in a variety of in vivo models, leading to regression

of large cell lung, colon, breast and prostate adenocarcinomas.

Breastin is a potent and selective preparation against some tumors.

It blocks cell- cycle progression and induces apoptosis in a diverse

range of human tumor types. Breastin profoundly inhibit tumor

growth in a variety of in vivo models, leading to regression of

B- 16 melanoma, Lewis- lung carcinoma and 180-sarcoma.

Breastin can be used as a supplementary medication to cancer

chemo-, hormone and/ or radiotherapy to restore and/ or

ameliorate the immune system of the patient and/ or to decrease

side effects and increase the antitumor effect of radiotherapy and

chemotherapeutics, particularly when used in combination with

taxol, adriamycin, cisplatin, 5-FU, alimta, cyclophosphamide,

mitomycin-C, navelbine, taxotere and topotecan, respectively, and

its use in the manufacture of a medication for the treatment of one

or more cancers of bladder, liver, ovary, pancreas, testicle, uterus

and vagina as well as pleuramesothelium and Hodgkin’s

lymphoma.

Administration Route: IM and OR.

Toxicities: Slight to moderate rise in temperature, nausea in 7- 10% of patients

plus diarrhea in 3-8 patients used Breastin.

Cancer indication: Solid tumors, breast cancer, colon cancer, lung cancer, prostate

cancer.

Can be used as a supplementary medication that can be taken

Alongside with some chemotherapy, radiotherapy and/ or

Hormonal therapy against some tumors.

CLINICAL STATUS BY INDICATION

Indication: Solid tumors

Latest Status: Phase II

Clinical History: In March 1988, dose esculation phase I clinical trial that will adminis.

Breastin 3- 4 mg IM to patients with solid tumors and 15- 20 mg OR as

an adjuvant route. The trial evaluates safety and tolerability of Breastin.

Indication: Solid tumors, including breast and colorectal tumors.

Clinical History: During the period between 1988- 2000 Breastin was clinically tested

on more than 283 patients (Phase II) suffering from different types

of tumors including Breast, colorectal, prostate, lung, skin, osteo-

sarcoma, larynx, bladder, glioblastoma...etc ,where Breastin

was administered 3- 4 mg using IM route and 15- 2 0 mg OR as an

adjuvant therapy. The trial was designed to assess how well Breastin

works, as well as to continue phase (I) safety assessments in a larger

group of patients.

More patients were enrolled in Breastin treatment from 2001 up to

date 2011 (more than 300 patients). These cases include maily

the 4 types of cancer responded to Breastin as shown in Phase II

clinical studies.

During the period between 2005- 2019 a total of more than 637

Cancer patients were treated with Breastin (lung, breast, colorectal,

Prostate…etc). Again Breastin showed remarkable potential effect

Against some cancers such as Breast, Colon, prostate, lung and

Pancreas.

This product was adopted by a Swiss-based company named Research Genetic Cancer Center (RGCC) since 2017 up to date. They are using it with other natural biological substances/ extracts (Onconomics Extracts). It focuses on testing using three methods: testing for direct effect on anti-cancer treatment, stimulating the immune system and inhibiting proliferation signals in the cancer cells that stimulate them to grow. The results are every encouraging.

................
................

In order to avoid copyright disputes, this page is only a partial summary.

Google Online Preview   Download